Treatment of Patients With Acute Sinusitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6777 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-03-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Bacterial Sinusitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Moxifloxacin MXF Avelox Sinusitis Acute bacterial sinusitis, ABS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Avelox (Moxifloxacin, BAY12-8039)

Intervention Type DRUG

Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avelox (Moxifloxacin, BAY12-8039)

Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in accordance with the local production information.

Exclusion Criteria

* Those specified in the local product information - contraindications and precautions must be considered.

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bayer HealthCare AG

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Austria

Site Status

Many Locations, , Bahrain

Site Status

Many Locations, , China

Site Status

Many Locations, , Egypt

Site Status

Many Locations, , France

Site Status

Many Locations, , Germany

Site Status

Many Locations, , Indonesia

Site Status

Many Locations, , Jordan

Site Status

Many Locations, , Kuwait

Site Status

Many Locations, , Lebanon

Site Status

Many Locations, , Malaysia

Site Status

Many Locations, , Netherlands

Site Status

Many Locations, , Pakistan

Site Status

Many Locations, , Philippines

Site Status

Many Locations, , Romania

Site Status

Many Locations, , Saudi Arabia

Site Status

Many Locations, , Singapore

Site Status

Many Locations, , United Arab Emirates

Site Status

Many Locations, , Yemen

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Bahrain China Egypt France Germany Indonesia Jordan Kuwait Lebanon Malaysia Netherlands Pakistan Philippines Romania Saudi Arabia Singapore United Arab Emirates Yemen

References

Explore related publications, articles, or registry entries linked to this study.

Mosges R, Desrosiers M, Arvis P, Heldner S. Characterisation of patients receiving moxifloxacin for acute bacterial rhinosinusitis in clinical practice: results from an international, observational cohort study. PLoS One. 2013 Apr 23;8(4):e61927. doi: 10.1371/journal.pone.0061927. Print 2013.

Reference Type DERIVED

PMID: 23626752 (View on PubMed)